Invictus RG’s Nektar Therapeutics NKTR Stock Holding History

Invictus RG’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-436	Closed	-$90K	–	696
2016 Q1	$90K	Buy	+436	New	+$83.7K	0.11%	300

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Invictus RG's NKTR Position: Q2 2016 in Review

Invictus RG sold out of Nektar Therapeutics (NKTR) in Q2 2016, closing a stake of 436 shares — an estimated $90K sold.

Invictus RG first reported a position in NKTR in Q1 2016 and held it in 1 quarter. The position peaked at $90K in Q1 2016. 177 funds tracked by Wall St. Rank hold NKTR as of Q2 2016.

Invictus RG reported no remaining Nektar Therapeutics position as of Q2 2016 after selling out during the quarter.
Invictus RG sold 436 Nektar Therapeutics shares in Q2 2016, an estimated $90K.
Invictus RG first reported a position in Nektar Therapeutics in Q1 2016 and held it in 1 quarter.
Invictus RG's Nektar Therapeutics position peaked at $90K in Q1 2016.
177 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2016.

Based on Invictus RG's 13F filing for Q2 2016, filed 15 Aug 2016.